Introducing our new and improved Hot Tort Report
Being industry experts, we pride ourselves on keeping our finger on the pulse of all things Multi District Litigation. This predominantly consists of providing our subscribers with competitive insights into where the money is being spent in hopes of informing your blueprint for advertising strategies. These cases can be highly lucrative, but are difficult to acquire, requiring significant investment and patience to secure high-value cases.
We’ve been working hard on an algorithm to deliver more than just monthly TV spends and are proud to announce that we are ready to unveil our HTR 2.0.
This new list offers an overview of dollars spent across TV, Meta, PPC, and more, assigning a score to each tort based on what we, as leaders in the law firm advertising space, are witnessing across these various platforms.
The Hot Tort Report:
June 2025
The Hottest in Mass Tort Spending: May 2025
Birth Control Injections
Featured Tort
Subscribe to the Hot Tort Report
What’s the Tort News?
Published: June, 2025. Advertising spend from multiple sources for a recent 30 day period.
If you have any questions, please contact us at national@whitehardt.com
#1 Birth Control Injections
After slipping to #2 last month, the Birth Control Injections mass tort has reclaimed the top spot with a solid 1.4-point increase in overall performance. Gains in both TV and Meta channels powered this climb, while WHii remains maxed out. With broad activity across all key platforms, this tort continues to bring the heat heading into summer.
CPA: $1,364 – $4,890
CPL: $682 – $2,445
For common criteria, please contact us.
#3 Ultra-Processed Foods
The Ultra-Processed Foods mass tort continues to climb, rising 1.1 points this month on the back of a substantial WHii boost. While Meta dipped slightly, this tort was able to maintain its #3 spot overall. There is growing attention to the long-term potential here, so now is the time to partner with Whitehardt to position your firm at the forefront of this emerging litigation.
For metrics such as CPA, CPL, and common criteria, please contact us.
#4 Roundup®
Sliding down to #4 this month with a sharp decline of around 5 points, Roundup® litigation saw a complete drop-off in TV activity. Meta and PPC remain strong, and WHii is holding moderate ground, but the absence of TV broadcast support has taken a noticeable toll. Despite the dip, Roundup® continues to command attention via digital channels.
CPA: $1,232
CPL: $739
For common criteria, please contact us.
#5 Video Game Addiction
The mass tort for Video Game Addiction takes #5 once again with an increase fueled by continued strength in Meta and a boost in PPC. WHii held steady, and TV remains inactive. Digital momentum is carrying this tort forward, keeping it highly visible. Whitehardt understands the distinct challenges and messaging needed for this emerging tort, and we’re ready to help your firm connect with the right audience.
CPA: $367
CPL: $169
Common Criteria: Child must be under 18 and spend 4+ hours per day, 5+ days per week, playing Minecraft, Fortnite, GTA 5, or Call of Duty. The child must also experience one or more of the following: addiction, poor school performance, school dropout, cognitive or developmental delays, chronic depression or anxiety, or self-harm/suicidal behavior.
#6 Birth Injury
This tort climbed three positions since last month, driven by coordinated gains in TV, PPC, and Meta. While WHii remains at zero, strong performance across all consumer-facing channels suggests that Birth Injury litigation has the potential to break into the top five next month.
For metrics such as CPA, CPL, and common criteria, please contact us.
#7 Hernia Mesh
The Hernia Mesh mass tort is slowly gaining ground, with an increase in WHii that brought it into the top ten this month. Activity across TV, Meta, and PPC remains moderate, and legal momentum is building; in the Covidien MDL, two bellwether cases were selected for discovery in April, and a separate case has been scheduled for trial in July 2026. As litigation advances behind the scenes, interest in this long-developing tort is rekindling.
For metrics such as CPA, CPL, and common criteria, please contact us.
#8 Paraquat
The Paraquat mass tort drops from 4th to 8th this month, driven largely by a pullback in TV spend. Meta and PPC remain relatively strong, and WHii holds modestly, but the loss of TV spending has slowed overall momentum. While visibility has dipped, Paraquat still maintains a solid digital presence.
CPA: $2,729
CPL: $1,165
Common Criteria: Diagnosis of Parkinson’s Disease or experiencing Parkinson’s-like symptoms after exposure to Paraquat.
#9 Takata Airbag Recall
Takata Airbag Recall spending held steady in performance this month but slipped two positions in the rankings as other fast-rising torts move ahead. TV remains the strongest channel, with Meta and PPC maintaining moderate activity. A recent $3 million jury verdict in South Florida related to a defective Takata airbag highlights the ongoing risks tied to this litigation, and it is not too late to get involved!
For metrics such as CPA, CPL, and common criteria, please contact us.
#10 AFFF
The AFFF mass tort held steady at #10 despite a slight rise in Meta activity that helped boost its overall score.
Plaintiffs in the MDL are seeking a consolidated bellwether trial for five personal injury cases, three involving kidney cancer and two involving testicular cancer, arguing that common exposure sources, shared defendants, and overlapping medical and scientific evidence justify grouping the cases for trial.
Though still near the bottom of the rankings, AFFF continues to maintain a consistent presence.
CPA: $3,500
CPL: $1,750
For common criteria, please contact us.
Mesothelioma
You may be noticing a tort missing from our new report. While Mesothelioma continues to dominate the competition when it comes to spend levels, Whitehardt finds that this tort is its own niche animal. These cases can be extremely fruitful, but hard to come by, requiring a high buy-in to get in the game and patience when landing that ringer of a case. We believe that Meso will remain a constant for some time, but in regards to many of the other drugs and devices we focus on in this monthly report, we’ve decided to move it to its own category. If you are interested in hearing the latest news on Meso or how Whitehardt may be currently seeking these cases, you can contact us here.
Whitehardt will continue to track meso spending from month to month, so if you are interested in ongoing meso spending, please reach out to us directly. Going forward, we will be excluding meso from these tort reports.
